spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Synthetic Biology Congress

Oxford Global Events - Synthetic Biology

8-9 November 2018
London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.

Our Synthetic Biology Congress will feature over 20 presentations and case studies demonstrating the latest synthetic biology tools and their therapeutic applications.

World renowned experts will give over 20 presentations across 2 interactive streams, including;

·         Synthetic Biology – Tool Development

·         Synthetic Biology – Applications 

View the Agenda here>> https://bit.ly/2Mton5I

This event will be co-located with our highly established 10th Annual Next Generation Sequencing and Clinical Diagnostics Congress, 6th Annual Single Cell Analysis Congress and the 4th Annual Genome Editing Congress 

For further information, prices & group discounts please contact d.dalby@oxfordglobal.co.uk

phone +44 (0)1865 248455
email d.dalby@oxfordglobal.co.uk
web https://bit.ly/2MtRRQY
email London
 
Print this page
Send to a friend
   
spacer
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>


News and Press Releases

Dynascan Discusses Company Advancements With Packaging Today Magazine

Dynascan’s Marketing Manager (MM) recently met up with Europe’s leading packaging magazine, Packaging Today. During the interview many topics were covered, and you can read the full article here, but below are a few highlights and brief summary of what was discussed…
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement